- Home
- HERZ vs BRNS Comparison
HERZ vs BRNS Comparison
Compare HERZ & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HERZ | BRNS |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 24.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HERZ | BRNS |
|---|---|---|
| Price | $18.73 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 3.8K | ★ 20.8K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.62 | $0.51 |
| 52 Week High | $19.30 | $2.91 |
Technical Indicators
Market Signals| Indicator | HERZ | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 54.23 |
| Support Level | $17.42 | $0.65 |
| Resistance Level | $19.08 | $0.75 |
| Average True Range (ATR) | 0.78 | 0.05 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 41.91 | 48.96 |
Price Performance
Historical ComparisonAbout HERZ Herzfeld Credit Income Fund Inc.
Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.